ESTRO 2024 - Abstract Book

S2338

Clinical - Urology

ESTRO 2024

toxicity to date. IPSS score and urinary quality of life scores recovered to baseline by 6months. Patient-reported outcomes showed no significant change in EQ-5D quality of life scores at 12 weeks and 1 year compared to baseline. There are no cases of biochemical relapse reported to date.

Figure 1. Percentage proportions of RTOG genitourinary (GU) toxicity prevalence (A) and RTOG gastrointestinal (GI) toxicity prevalence (B) by acute timepoints. Abbreviations: GI = gastrointestinal, GU = genitourinary, RTOG = Radiation Therapy Oncology Group, SBRT = stereotactic body radiotherapy.

Conclusion:

CyberKnife SBRT delivered to a dose of 36.25Gy to the prostate gland and a simultaneous integrated boost to DIL up to 47.5Gy is feasible and well tolerated. Rates of acute and late GU and GI toxicity are comparable to other recent contemporary SBRT trials and series with focal boost.

Keywords: Prostate Cancer, SBRT, dominant lesion

References:

[1] Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Robert ;, et al. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. J Clin Oncol . 2021;39:787 – 96.

520

Digital Poster

Low PSA nadir is a powerful predictor of tumour control and survival after HDR-brachytherapy boost

Max Peters 1 , Tonnis T. Nuver 1 , Marnix J.A. Rasing 1 , Margo C. Noordhoek 1 , Marie A.D. Haverkort 2 , Erik C. Schimmel 2 , Wout J. Schoevers 1 , Michal D. Czerwinski 2 , Kasper L. Pasma 2 , André W. Minken 1